Compositions comprising bacterial strains

1. A pharmaceutical composition that comprises a therapeutically effective amount of a lyophilized bacteria strain of the species Blautia hydrogenotrophica to treat visceral hypersensitivity in a subject in need thereof, wherein the therapeutically effective amount comprises from 1×10 3 to 1×10 12 colony forming units (CFU)/g of the lyophilized bacteria strain, with respect to total weight of said pharmaceutical composition, wherein the bacteria strain comprises the 16s rRNA gene sequence set forth in SEQ ID NO: 5;

an oxygen scavenger that is vitamin C; a compound selected from the group consisting of inulin, transgalacto-oligosaccharides, fructo-oligosaccharides, isomalt-oligosaccharides, pectins, xylo-oligosaccharides, chitosan-oligosaccharides, beta-glucans, arable gum modified and resistant starches, polydextrose, D-tagatose, acacia fibers, carob, oats, citrus fibers, non-digestible carbohydrates, and sugar alcohols, or any combination thereof; and

a pharmaceutically acceptable excipient, diluent, or carrier;

wherein the therapeutically effective amount is sufficient to increase an amount of butyrate in the gastrointestinal tract of the subject relative to a corresponding amount of butyrate prior to the administration or to decrease an amount of a sulphide reducing bacteria in the gastrointestinal tract of the subject relative to a corresponding amount of the sulphide reducing bacteria prior administration; and

wherein said pharmaceutical composition is a solid enteric formulation and is encapsulated.

2. The pharmaceutical composition of claim 1 , wherein said bacteria strain colonizes an intestine of a subject when administered to said subject.

3. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is formulated for oral or rectal delivery.

4. The pharmaceutical composition of claim 1 , wherein said bacteria strain is the bacteria strain deposited under accession number DSM 10507, DSM 14294, or a biotype thereof.

5. A method of treating visceral hypersensitivity in a subject in need thereof comprising administering to said subject a pharmaceutical composition that comprises a therapeutically effective amount of a lyophilized bacteria strain of the species Blautia hydrogenotrophica to treat visceral hypersensitivity in the subject, wherein the bacteria strain comprises the 16s rRNA gene sequence set forth in SEQ ID NO: 5; an oxygen scavenger that is vitamin C; a compound selected from the group consisting of inulin, transgalacto-oligosaccharides, fructo-oligosaccharides, isomalt-oligosaccharides, pectins, xylo-oligosaccharides, chitosan-oligosaccharides, beta-glucans, arable gum modified and resistant starches, polydextrose, D-tagatose, acacia fibers, carob, oats, citrus fibers, non-digestible carbohydrates, and sugar alcohols, or any combination thereof; and a pharmaceutically acceptable excipient, diluent, or carrier;

wherein said therapeutically effective amount comprises from 1×10 3 to 1×10 12 colony forming units (CFU) per gram of the lyophilized bacteria strain with respect to total weight of said pharmaceutical composition;

wherein said pharmaceutical composition is a solid enteric formulation and is encapsulated; and

wherein said therapeutically effective amount is sufficient to increase an amount of butyrate in the gastrointestinal tract of the subject relative to a corresponding amount of butyrate prior to the administration or to decrease an amount of a sulphide reducing bacteria in the gastrointestinal tract of the subject relative to a corresponding amount of the sulphide reducing bacteria prior administration.

6. The method of claim 5 , wherein said bacteria strain colonizes an intestine of said subject when administered to said subject.

7. The method of claim 5 , wherein said bacteria strain is the Blautia hydrogenotrophica bacteria strain deposited under accession number DSM 10507, DSM 14294, or a biotype thereof.

8. The method of claim 5 , wherein said administering comprises oral, rectal, nasal, buccal, sublingual, or subcutaneous administration.

9. The method of claim 5 , wherein said subject has irritable bowel syndrome.

10. The method of claim 5 , wherein said subject is a human.